Latest news with #CACMid&Small
Yahoo
2 days ago
- Business
- Yahoo
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France, June 05, 2025--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ("Tribunal des activités économiques de Lyon") decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit View source version on Contacts PHAXIAM Thibaut du Fayet CEO+33 4 78 74 44 38investors@ NewCap Mathilde Bohin / Dušan Orešanský Investor RelationsArthur RouilléMedia Relations+33 1 44 71 94 94phaxiam@
Business Wire
2 days ago
- Business
- Business Wire
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ('Tribunal des activités économiques de Lyon') decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
Yahoo
23-05-2025
- Business
- Yahoo
Assystem: Combined General Meeting of 23 May 2025 - Voting results and dividend for financial year 2024
Combined General Meeting of 23 May 2025Voting results and dividend for financial year 2024 Paris-La Défense, on 23 May 2025, 6.00 p.m (CET) – Assystem S.A. (ISIN: FR0000074148 – ASY), confirms that its Combined General Meeting was held today, at the Centre de conférences Etoile Saint Honoré located at 21-25 rue Balzac, 75008 Paris, chaired by Mr. Dominique Louis, Chairman and CEO. The quorum was 85.417% and the General Meeting approved all resolutions submitted to vote except for the fourth resolution (Approval of related-party agreement). In particular, the General Meeting: approved the parent company and consolidated financial statements for the year ended on December 31st, 2024, also decided the payment of a dividend of €1.00 per share for the 2024 financial year, which remainder will be paid with the following schedule: 8 July 2025: ex-date, 9 July 2025 (after-market closure): record date, 10 July 2025: payment date, The results of votes will be available on the Company's website ( ABOUT ASSYSTEM Assystem, one of the world's leading independent nuclear engineering companies, is committed to accelerating the energy transition. With more than 55 years of experience in highly regulated sectors with stringent safety and security constraints, the Group provides engineering and project management services as well as digital solutions and services to optimize the performance of complex infrastructure assets throughout their life its 12 countries of operation, Assystem's 7,750 experts are supporting energy transition. To achieve an affordable low carbon energy supply, Assystem is committed to the development of low carbon electricity (nuclear, renewables and electricity grids) and clean hydrogen. The Group is also helping drive the use of low carbon electricity in industrial sectors such as forms part of the Euronext Tech Leaders, CAC Small, CAC Mid & Small, CAC Industrials, CAC All-Tradable, CAC All-Share, PEA-PME 150 and MSCI Small cap Index France indices. For more information, please visit CONTACTS Malène Korvin – Chief Financial Officer - mkorvin@ - Tel.: +33 (0)1 41 25 29 00 Anne-Charlotte Dagorn – Communications Director - acdagorn@ - Tel.: +33 (0)6 83 03 70 29 Agnès Villeret – Komodo – Investor relations - - Tel: +33 (0)6 83 28 04 15 Attachment ASSYSTEM PR Post Shareholders meeting 2025 - Voting results and dividendSign in to access your portfolio
Business Wire
22-05-2025
- Business
- Business Wire
PHAXIAM Therapeutics: Postponement of the Offer Review Hearing
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ('Tribunal des activités économiques de Lyon') decided, during a hearing held on May 21, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 4, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted will likely not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
Business Wire
05-05-2025
- Business
- Business Wire
PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces the continuation of its observation period under the receivership procedure. The Commercial Court of Lyon decided on April 30, 2025 to extend the observation period and set the bid review hearing on May 21, 2025. This extension of the observation period will enable potential buyers to improve their offers. As a reminder, whether or not a bid is accepted, the Commercial Court of Lyon will in any case soon pronounce the judicial liquidation of the Company. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
